SEQENS is a global leader in pharmaceutical solutions and specialty ingredients.

They provide a range of products, including generic and custom APIs, intermediates, and excipients for pharmaceuticals, along with ingredients for personal care and specialty chemicals.

With 16 production sites and 9 R&D centers across 9 countries, SEQENS serves over 1,500 customers in more than 80 countries.

In 2021, Private equity group SK Capital Partners has completed the acquisition of a majority stake in French firm Seqens, at the same time merging portfolio company Wavelength Pharmaceuticals into Seqens.